Bicocca Open Archive

Logo unimib boa
MOLOGNI, LUCA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 14.342
AS - Asia 9.365
EU - Europa 7.182
SA - Sud America 1.433
AF - Africa 260
OC - Oceania 28
Continente sconosciuto - Info sul continente non disponibili 18
Totale 32.628
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 13.624
SG - Singapore 3.110
CN - Cina 1.990
IT - Italia 1.975
VN - Vietnam 1.692
HK - Hong Kong 1.079
BR - Brasile 1.077
DE - Germania 1.015
RU - Federazione Russa 990
IE - Irlanda 654
SE - Svezia 627
CA - Canada 584
GB - Regno Unito 382
FR - Francia 352
UA - Ucraina 316
IN - India 301
BD - Bangladesh 183
FI - Finlandia 182
PL - Polonia 162
KR - Corea 155
AR - Argentina 145
ID - Indonesia 136
ES - Italia 123
TR - Turchia 122
IQ - Iraq 93
NL - Olanda 91
JP - Giappone 90
ZA - Sudafrica 86
PK - Pakistan 79
MX - Messico 74
BE - Belgio 70
CH - Svizzera 61
EC - Ecuador 46
AT - Austria 45
MA - Marocco 45
UZ - Uzbekistan 44
SA - Arabia Saudita 42
PH - Filippine 41
CO - Colombia 39
DK - Danimarca 36
VE - Venezuela 34
CL - Cile 29
KE - Kenya 28
LT - Lituania 26
TN - Tunisia 26
PE - Perù 24
PY - Paraguay 23
AU - Australia 22
NP - Nepal 19
ET - Etiopia 18
EG - Egitto 17
JO - Giordania 17
TW - Taiwan 17
IR - Iran 16
AE - Emirati Arabi Uniti 14
AZ - Azerbaigian 14
EU - Europa 14
MY - Malesia 14
TH - Thailandia 14
CR - Costa Rica 10
OM - Oman 10
UY - Uruguay 10
CZ - Repubblica Ceca 9
PS - Palestinian Territory 9
DO - Repubblica Dominicana 8
KZ - Kazakistan 8
RO - Romania 8
HN - Honduras 7
MU - Mauritius 7
AL - Albania 6
AO - Angola 6
GE - Georgia 6
IL - Israele 6
KG - Kirghizistan 6
NI - Nicaragua 6
NO - Norvegia 6
PA - Panama 6
TT - Trinidad e Tobago 6
BG - Bulgaria 5
BO - Bolivia 5
DZ - Algeria 5
GR - Grecia 5
JM - Giamaica 5
MD - Moldavia 5
NG - Nigeria 5
NZ - Nuova Zelanda 5
BH - Bahrain 4
LB - Libano 4
MK - Macedonia 4
MO - Macao, regione amministrativa speciale della Cina 4
RS - Serbia 4
SK - Slovacchia (Repubblica Slovacca) 4
SV - El Salvador 4
SY - Repubblica araba siriana 4
AM - Armenia 3
HU - Ungheria 3
LA - Repubblica Popolare Democratica del Laos 3
LK - Sri Lanka 3
LY - Libia 3
PR - Porto Rico 3
Totale 32.574
Salva come PNG Salva come JPEG
Città #
Ann Arbor 1.939
Singapore 1.730
Ashburn 1.453
Hong Kong 1.045
San Jose 897
Woodbridge 727
Milan 714
Fairfield 689
Frankfurt am Main 657
Dublin 640
Chandler 602
Ho Chi Minh City 516
Houston 459
Wilmington 445
Hanoi 434
Toronto 404
New York 398
Dallas 385
Los Angeles 346
Beijing 297
Jacksonville 268
Seattle 268
Hefei 263
Santa Clara 259
Cambridge 248
Dearborn 247
The Dalles 224
Chicago 216
Princeton 172
Seoul 139
Shanghai 132
Lauterbourg 128
Nanjing 125
São Paulo 122
Boardman 112
Buffalo 112
Council Bluffs 109
Munich 101
Moscow 94
Jakarta 93
Altamura 83
Lawrence 79
Da Nang 78
Helsinki 78
Tokyo 75
Warsaw 72
Lodz 70
Haiphong 62
Brussels 61
Orem 61
London 52
Johannesburg 51
Montreal 50
Guangzhou 49
San Diego 49
Phoenix 48
Rio de Janeiro 47
Atlanta 45
Nuremberg 45
Zurich 45
Lachine 44
Rome 44
Chennai 42
Denver 42
Kent 41
Hải Dương 40
Poplar 40
Turku 40
Fremont 39
Brooklyn 37
Baghdad 36
Lissone 36
Shenyang 36
Stockholm 36
Tashkent 36
Desio 33
Nanchang 33
Andover 31
Amsterdam 30
Biên Hòa 30
Changsha 29
Ottawa 29
Romola 29
Boston 28
Lahore 28
Pune 28
Ankara 27
Göttingen 27
Jinan 27
Salt Lake City 27
Seveso 26
Washington 26
Ha Long 25
Monza 25
Paris 25
Tianjin 25
Dhaka 24
Manchester 24
San Francisco 24
Buenos Aires 23
Totale 20.681
Salva come PNG Salva come JPEG
Nome #
Lorlatinib treatment elicits multiple on- and off-target mechanisms of resistance in ALK-driven cancer 536
Long-term efficacy and safety of crizotinib in relapsed ALK positive lymphoma patients: clinical and biological correlates 450
Behavior of the anti-apoptotic BCL-2 protein in non-small-cell lung cancer cell models in response to treatments with ALK inhibitors and its potential dual BCL2-ALK inhibition 448
Wiskott–Aldrich syndrome protein (WASP) is a tumor suppressor in T cell lymphoma 443
Loss of CDKN2B expression as a potential marker of resistance to CDK4/6 inhibitor in Luminal Breast Cancer cells 430
Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency 429
Recurrent SETBP1 mutations in atypical chronic myeloid leukemia 410
Three novel patients derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors 403
A Compound L1196M/G1202R ALK Mutation in a Patient with ALK-Positive Lung Cancer with Acquired Resistance to Brigatinib Also Confers Primary Resistance to Lorlatinib 401
An Imatinib–non-responsive patient with an ABL Leu387Trp mutation achieves cytogenetic and molecular response under bosutinib: Case report and biological characterization 394
Integrated Genomic, Functional, and Prognostic Characterization of Atypical Chronic Myeloid Leukemia 382
Synergistic activity of ALK and mTOR inhibitors for the treatment of NPM-ALK positive lymphoma 380
Epitope mapping of spontaneous autoantibodies to anaplastic lymphoma kinase (ALK) in non-small cell lung cancer 378
Entrectinib, a Pan-TRK, ROS1, and ALK inhibitor with activity in multiple molecularly defined cancer indications 378
First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis 377
Characterization of compound 584, an Abl kinase inhibitor with lasting effects 373
Phase two study of crizotinib in patients with anaplastic lymphoma kinase (ALK) positive anaplastic large cell lymphoma relapsed/refractory to chemotherapy 370
Concomitant BCORL1 and BRAF Mutations in Vemurafenib-Resistant Melanoma Cells 362
TWIST1 Upregulation Is a Potential Target for Reversing Resistance to the CDK4/6 Inhibitor in Metastatic Luminal Breast Cancer Cells 354
Integrative multi-omics analysis enables a comprehensive characterization of prostate cancer and unveils metastasis-associated candidate biomarkers 345
Integrating mutational profiles and transcriptional data with ASTUTE to elucidate the key molecular functions involved in the pathogenesis of cancer 344
Conditioned Medium of Mesenchymal Stromal Cells Loaded with Paclitaxel Is Effective in Preclinical Models of Triple-Negative Breast Cancer (TNBC) 337
Abstract 902: In vitro andin vivocharacterization of resistance to lorlatinib treatment in ALK mutated cancers 335
Synthesis and biological evaluation of benzo[4,5]imidazo[1,2-c]pyrimidine and benzo[4,5]imidazo[1,2-a]pyrazine derivatives as anaplastic lymphoma kinase inhibitors 334
Bcr-Abl stabilizes beta-catenin in chronic myeloid leukemia through its tyrosine phosphorylation 333
ERG deregulation induces PIM1 over-expression and aneuploidy in prostate epithelial cells 333
A New BCR-ABL1 Mutation (L248R) Is Highly Resistant to Imatinib, Bosutinib, Nilotinib and Dasatinib, but Can Be Inhibited by AP-24534 and DCC-2036 333
Synthesis, structure-activity relationship and crystallographic studies of 3-substituted indolin-2-one RET inhibitors 332
Oncogenic fusion tyrosine kinases as molecular targets for anti-cancer therapy 331
Mitochondrial Hyperactivation and Enhanced ROS Production are Involved in Toxicity Induced by Oncogenic Kinases Over-Signaling 329
Anaplastic Lymphoma Kinase (ALK) Inhibitors Enhance Phagocytosis Induced by CD47 Blockade in Sensitive and Resistant ALK-Driven Malignancies 324
Inhibition of RET tyrosine kinase by SU5416 322
Treatment efficacy and resistance mechanisms using the second-generation ALK inhibitor AP26113 in human NPM-ALK-positive anaplastic large cell lymphoma 321
Oncoscore, a Novel, Internet-Based Tool to Assess the Oncogenic Potential of Genes Can Differentiate Between CP-CML and BC-CML Associated Genes, and Between CP-CML Patients with Good and Bad Prognosis 319
Epigenetic Silencing of the Proapoptotic Gene BIM in Anaplastic Large Cell Lymphoma through an MeCP2/SIN3a Deacetylating Complex 313
Immune Recognition of ALK Fusion Proteins in Patients with ALK-Rearranged Non-Small Cell Lung Cancer 313
Crizotinib-Resistant NPM-ALK Mutants Confer Differential Sensitivity to Unrelated Alk Inhibitors 311
Dissection of the RET/ß-catenin interaction in the TPC1 thyroid cancer cell line 309
Recurrent SETBP1 Mutations in Atypical Chronic Myeloid Leukemia 307
Phase ii study with crizotinib in patients with anaplastic lymphoma kinase (alk)-positive lymphoma relapsed/refractory to chemotherapy 306
Evolutionary signatures of human cancers revealed via genomic analysis of over 35,000 patients 305
Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase 304
Dual kinase targeting in leukemia 304
Structural insights into the ATP binding pocket of the anaplastic lymphoma kinase by site-directed mutagenesis, inhibitor binding analysis, and homology modeling 295
Design, synthesis, and biological activity of urea derivatives as anaplastic lymphoma kinase inhibitors 289
Recurrent somatic mutations of FAT family cadherins induce an aggressive phenotype and poor prognosis in anaplastic large cell lymphoma 287
New pan-ALK inhibitor-resistant EML4::ALK mutations detected by liquid biopsy in lung cancer patients 287
Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes 286
Synergistic effects of combined Wnt/KRAS inhibition in colorectal cancer cells 285
DNA Damage Response (DDR) Is Associated With Treatment-free Remission in Chronic Myeloid Leukemia Patients 279
Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients 279
Efficacy of a cancer vaccine against ALK-rearranged lung tumors 279
Hb Monza: A novel extensive HBB duplication with preserved α-β subunit interaction and unstable hemoglobin phenotype 278
Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis 277
Characterization of cancer subtypes associated with clinical outcomes by multi-omics integrative clustering 274
We shall overcome (drug resistance) some day 272
STAT3 and TP53 mutations associate with poor prognosis in anaplastic large cell lymphoma 272
Synergistic drug combinations prevent resistance in ALK+ anaplastic large cell lymphoma 270
Expression, purification, and inhibition of human RET tyrosine kinase 266
Characterization of the transcriptional landscape of atypical Chronic Myeloid Leukemia at single-cell resolution 261
Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK 260
Effects of blocking CD24 and CD47 'don't eat me' signals in combination with rituximab in mantle-cell lymphoma and chronic lymphocytic leukaemia 256
A rapid method for the purification of wild-type and V804M mutant ret catalytic domain: A tool to study thyroid cancer 256
Colorectal tumors are effectively eradicated by combined inhibition of {beta}-catenin, KRAS, and the oncogenic transcription factor ITF2 256
Comprehensive analysis of mutational processes across 20 000 adult and pediatric tumors 255
Prognostic Biomarkers in Breast Cancer via Multi-Omics Clustering Analysis 254
Valproic acid enhances bosutinib cytotoxicity in colon cancer cells 253
SETBP1 accumulation induces P53 inhibition and genotoxic stress in neural progenitors underlying neurodegeneration in Schinzel-Giedion syndrome 251
Abstract 3583: Drug-resistant NPM/ALK mutants show different sensitivity to second generation tyrosine kinase inhibitors 243
Novel ALK mutations in EML4::ALK+ NSCLC resistant to TKIs identified by liquid biopsy 238
Balanced SET levels favor the correct enhancer repertoire during cell fate acquisition 237
Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting 234
Novel targeted therapeutics for MEN2 234
NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922 233
β-catenin knockdown promotes NHERF1-mediated survival of colorectal cancer cells: Implications for a double-targeted therapy 233
IL10RA modulates crizotinib sensitivity in NPM1-ALK+ anaplastic large cell lymphoma 230
Repurposing pexmetinib as an inhibitor of TKI-resistant BCR::ABL1 229
Synergistic Activity of ALK and mTOR Inhibitors for the Treatment of NPM-ALK Positive Lymphoma 226
Whole exome sequencing reveals NOTCH1 mutations in anaplastic large cell lymphoma and points to Notch both as a key pathway and a potential therapeutic target 226
New advances in liquid biopsy technologies for anaplastic lymphoma kinase (Alk)—positive cancer 225
Abstract 2920: Excess of cytoplasmic NPM-ALK driven oncogenic signaling is toxic and promotes cellular apoptosis and drug dependency 223
Validation of a new NGS-based myeloid panel in acute myeloid leukemia: A single-center experience 220
BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells 220
Targeting CCR7-PI3Kγ overcomes resistance to tyrosine kinase inhibitors in ALK-rearranged lymphoma 219
Somatic mutations identified at diagnosis by exome sequencing can predict response to imatinib in chronic phase chronic myeloid leukemia (CML) patients 219
First-Hit SETBP1 Mutations Cause a Myeloproliferative Disorder with Bone Marrow Fibrosis 217
Unique substrate specificity of Anaplastic Lymphoma Kinase (ALK): development of phosphoacceptor peptides for the assay of ALK activity 217
First-Hit SETBP1 Mutations Cause a Myeloproliferative Disorder with Bone Marrow Fibrosis Mimicking Triple Negative Myelofibrosis 215
Focal adhesion kinase (FAK) binds RET kinase via its FERM domain, priming a direct and reciprocal RET-FAK transactivation mechanism 212
Integrative analysis of KEAP1/NFE2L2 alterations across 3600+ tumors reveals an NRF2 expression signature as a prognostic biomarker in cancer 210
Targeted deletion of the muscular dystrophy gene myotilin does not perturb muscle structure or function in mice 210
Current and future treatment of anaplastic lymphoma kinase-rearranged cancer 209
Inhibitors of the RET tyrosine kinase based on a 2-(alkylsulfanyl)-4-(3- thienyl)nicotinonitrile scaffold 209
Resistance Profile of the BCR/ABL Inhibitor Bosutinib Using a High Throughput random Mutagenesis Assay 208
Discovery of Novel α-Carboline Inhibitors of the Anaplastic Lymphoma Kinase 205
Gut virome-colonising Orthohepadnavirus genus is associated with ulcerative colitis pathogenesis and induces intestinal inflammation in vivo 203
The novel PIM1 inhibitor NMS-P645 reverses PIM1-Dependent effects on TMPRSS2/ERG positive Prostate cancer cells and shows anti-proliferative activity in combination with PI3K inhibition 202
Alfa-carboline inhibitors of npm-alk, ret, and bcr-abl 200
Erratum: Treatment efficacy and resistance mechanisms using the second-generation ALK inhibitor AP26113 in human NPM-ALK-positive anaplastic large cell lymphoma (Molecular Cancer Research (2015) 13 (775-783)) 196
Inhibition of the anti-apoptotic protein BCL2 in EML4-ALK cell models as a second proposed therapeutic target for non-small cell lung cancer 194
Totale 29.215
Salva come PNG Salva come JPEG
Categoria #
all - tutte 103.078
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 103.078
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021174 0 0 0 0 0 0 0 0 0 0 0 174
2021/20221.316 112 154 136 70 54 102 80 72 62 119 147 208
2022/20232.642 289 734 209 237 176 353 28 138 180 134 85 79
2023/20242.204 113 87 98 113 255 562 400 68 177 57 55 219
2024/20255.508 275 476 319 278 440 200 369 193 548 880 492 1.038
2025/202614.391 1.935 1.030 1.206 1.673 1.644 753 2.020 617 1.126 1.284 817 286
Totale 33.351